Branham Law, LLP announces an investigation has been launched into the actions of the officers and directors of Chelsea Therapeutics International, Ltd. (Nasdaq: CHTP) (“Chelsea” or the “Company”) for possible violations of securities and shareholder protection laws. If you purchased shares of Chelsea between November 3, 2008 and March 28, 2012 or have relevant information regarding this suit, you are urged to contact attorney Trey Branham at email@example.com or toll free at (855) 722-5910. The investigation focuses on whether the Company and its executives violated federal securities laws by failing to disclose that: (1) Chelsea’s Northera (droxidopa) product, an orally-active synthetic precursor of norepinephrine being developed for the treatment of symptomatic neurogenic orthostatic hypotension, would not receive approval from the U.S. Food and Drug Administration; and (2) the Company’s numerous statements regarding the safety and efficacy of the product, as well as reportedly positive results from Northera’s clinical trials, were materially false and misleading. Branham Law, LLP has significant experience in shareholder representation nationwide.
More from Press Releases
NFL Pushes for Regulation Following Supreme Court's Sports Gambling Ruling
The Supreme Court rules that previous congressional action forbidding states from legalizing sports betting was unconstitutional.
Walmart CEO: 'We Are Transforming Globally' With Flipkart
On its investor call on Wednesday morning, Walmart discusses the Flipkart deal.
March 24 Full-Day Course Offering: Professional Approach to Trading SPX
OptionsProfits, the CBOE, and Option Pit are hosting a class on March 24 that covers a wide variety of methods to trade the S&P 500.